BIND Therapeutics Prices Public Offering of Common Stock and Warrants to Purchase Common Stock

CAMBRIDGE, Mass.--()--BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins™, today announced the pricing of its underwritten public offering of 3,739,130 units at the public offering price of $5.75 per unit. Each unit consists of one share of common stock and six-tenths (0.6) of a warrant to purchase one share of common stock with an exercise price of $6.60 per share. All units in the offering are to be sold by BIND. The gross proceeds to BIND from this offering are expected to be approximately $21.5 million, not including any future proceeds from the exercise of the warrants.

Cowen and Company and Stifel are acting as joint book-running managers for the offering. JMP Securities is acting as lead manager and Oppenheimer & Co. is acting as co-manager for the offering.

The offering is being made pursuant to an effective shelf registration statement on Form S-3 that was filed with the U.S. Securities and Exchange Commission (SEC) on October 1, 2014. A preliminary prospectus supplement describing the terms of the offering has been filed with the SEC. A final prospectus supplement will be filed with the SEC and will form a part of the effective registration statement. Copies of the final prospectus supplement and accompanying prospectus relating to this offering may be obtained by contacting Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, or by phone (631) 274-2806 or fax (631) 254-7140; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA, 94104, by telephone at (415) 364-2720 or by email to syndprospectus@stifel.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor shall there be any sale of these securities, in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

Contacts

Media:
The Yates Network
Gina Nugent, 617-460-3579
gina@theyatesnetwork.com
or
Investors:
Stern Investor Relations, Inc.
Beth DelGiacco, 212-362-1200
BIND@sternir.com

Website

Release Summary

BIND announced the pricing of its underwritten public offering

BIND Therapeutics, Inc.